Indivior Has Some Explaining To Do At R&D Day After Nasal Naloxone Spray Fails To Get FDA OK
This article was originally published in Scrip
Executive Summary
News that Indivior PLC's nasal naloxone spray has failed to get FDA approval is a painful setback for the addiction company given that it has already seen two other products delayed this year - and should make the recently spun-off group's Dec. 9 R&D day in New York City that much more interesting.